chlorzoxazone has been researched along with Morbid Obesity in 2 studies
Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Incorporation of the relevant physiological and biochemical changes into predictive bottom-up pharmacokinetic models in order to optimize dosage regimens may offer a logical way forward for the cases where no clinical data exist." | 1.37 | Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. ( Aarabi, M; Allabi, AC; Almond, LM; Ghobadi, C; Jamei, M; Johnson, TN; Rostami-Hodjegan, A; Rowland-Yeo, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghobadi, C | 1 |
| Johnson, TN | 1 |
| Aarabi, M | 1 |
| Almond, LM | 1 |
| Allabi, AC | 1 |
| Rowland-Yeo, K | 1 |
| Jamei, M | 1 |
| Rostami-Hodjegan, A | 1 |
| Emery, MG | 1 |
| Fisher, JM | 1 |
| Chien, JY | 1 |
| Kharasch, ED | 1 |
| Dellinger, EP | 1 |
| Kowdley, KV | 1 |
| Thummel, KE | 1 |
2 other studies available for chlorzoxazone and Morbid Obesity
| Article | Year |
|---|---|
Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.
Topics: Adolescent; Adult; Aged; Benzodiazepines; Body Weights and Measures; Caffeine; Chlorzoxazone; Comput | 2011 |
CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease.
Topics: Blood Glucose; Chlorzoxazone; Cytochrome P-450 CYP2E1; Enzyme Activation; Fatty Liver; Female; Gastr | 2003 |